Not recruiting
Bladder transitional cell carcinoma+1
Not recruitingStudy of MK-3120 for patients with high-risk non-muscle invasive bladder cancer who have not received or have received BCG treatment
InvestigationalNo placebo
Study of MK-3120 for patients with high-risk non-muscle invasive bladder cancer who have not received or have received BCG treatment
InvestigationalNo placebo
- Disease:Bladder transitional cell carcinomaCarcinoma in situ
- Substances:SKB410
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:SKB410
- Sponsor:Merck Sharp & Dohme LLC
